305 related articles for article (PubMed ID: 21289283)
1. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.
Cole KA; Huggins J; Laquaglia M; Hulderman CE; Russell MR; Bosse K; Diskin SJ; Attiyeh EF; Sennett R; Norris G; Laudenslager M; Wood AC; Mayes PA; Jagannathan J; Winter C; Mosse YP; Maris JM
Proc Natl Acad Sci U S A; 2011 Feb; 108(8):3336-41. PubMed ID: 21289283
[TBL] [Abstract][Full Text] [Related]
2. The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells.
Gu L; Chu P; Lingeman R; McDaniel H; Kechichian S; Hickey RJ; Liu Z; Yuan YC; Sandoval JA; Fields GB; Malkas LH
EBioMedicine; 2015 Dec; 2(12):1923-31. PubMed ID: 26844271
[TBL] [Abstract][Full Text] [Related]
3. FGFR2 loss sensitizes MYCN-amplified neuroblastoma CHP134 cells to CHK1 inhibitor-induced apoptosis.
Ando K; Ohira M; Takada I; Cázares-Ordoñez V; Suenaga Y; Nagase H; Kobayashi S; Koshinaga T; Kamijo T; Makishima M; Wada S
Cancer Sci; 2022 Feb; 113(2):587-596. PubMed ID: 34807483
[TBL] [Abstract][Full Text] [Related]
4. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
[TBL] [Abstract][Full Text] [Related]
5. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.
Walton MI; Eve PD; Hayes A; Valenti MR; De Haven Brandon AK; Box G; Hallsworth A; Smith EL; Boxall KJ; Lainchbury M; Matthews TP; Jamin Y; Robinson SP; Aherne GW; Reader JC; Chesler L; Raynaud FI; Eccles SA; Collins I; Garrett MD
Clin Cancer Res; 2012 Oct; 18(20):5650-61. PubMed ID: 22929806
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.
Colicchia V; Petroni M; Guarguaglini G; Sardina F; Sahún-Roncero M; Carbonari M; Ricci B; Heil C; Capalbo C; Belardinilli F; Coppa A; Peruzzi G; Screpanti I; Lavia P; Gulino A; Giannini G
Oncogene; 2017 Aug; 36(33):4682-4691. PubMed ID: 28394338
[TBL] [Abstract][Full Text] [Related]
7. Carcinogen-induced S-phase arrest is Chk1 mediated and caffeine sensitive.
Guo N; Faller DV; Vaziri C
Cell Growth Differ; 2002 Feb; 13(2):77-86. PubMed ID: 11864911
[TBL] [Abstract][Full Text] [Related]
8. Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells.
Ando K; Nakamura Y; Nagase H; Nakagawara A; Koshinaga T; Wada S; Makishima M
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362335
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro.
Wang Z; Førsund MS; Trope CG; Nesland JM; Holm R; Slipicevic A
Cancer Med; 2018 Aug; 7(8):3955-3964. PubMed ID: 29963769
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma.
Russell MR; Levin K; Rader J; Belcastro L; Li Y; Martinez D; Pawel B; Shumway SD; Maris JM; Cole KA
Cancer Res; 2013 Jan; 73(2):776-84. PubMed ID: 23135916
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage.
Syljuåsen RG; Sørensen CS; Hansen LT; Fugger K; Lundin C; Johansson F; Helleday T; Sehested M; Lukas J; Bartek J
Mol Cell Biol; 2005 May; 25(9):3553-62. PubMed ID: 15831461
[TBL] [Abstract][Full Text] [Related]
12. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
13. Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors.
Wang WT; Catto JW; Meuth M
Oncogene; 2015 May; 34(22):2887-96. PubMed ID: 25043304
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
[TBL] [Abstract][Full Text] [Related]
15. DNA damage-induced CHK1 autophosphorylation at Ser296 is regulated by an intramolecular mechanism.
Okita N; Minato S; Ohmi E; Tanuma S; Higami Y
FEBS Lett; 2012 Nov; 586(22):3974-9. PubMed ID: 23068608
[TBL] [Abstract][Full Text] [Related]
16. GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling.
Duffy DJ; Krstic A; Schwarzl T; Higgins DG; Kolch W
Mol Cancer Ther; 2014 Feb; 13(2):454-67. PubMed ID: 24282277
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
[TBL] [Abstract][Full Text] [Related]
18. Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase.
Petermann E; Maya-Mendoza A; Zachos G; Gillespie DA; Jackson DA; Caldecott KW
Mol Cell Biol; 2006 Apr; 26(8):3319-26. PubMed ID: 16581803
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of checkpoint kinase 1 abrogates G2/M checkpoint activation and promotes apoptosis under heat stress.
Furusawa Y; Iizumi T; Fujiwara Y; Zhao QL; Tabuchi Y; Nomura T; Kondo T
Apoptosis; 2012 Jan; 17(1):102-12. PubMed ID: 22080164
[TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
